Virus‐delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Annals of Neurology

• Publication date

  2005-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ana.20453PMID 15852369PMCID PMC1351126
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model

  2005cited by this paper
• Infectious Titer Assay for Adeno-Associated Virus Vectors with Sensitivity Sufficient to Detect Single Infectious Events

  2004cited by this paper
• Benefit of valproic acid in suppressing disease progression of ALS model mice

  2004cited by this paper
• Unraveling the mechanisms involved in motor neuron degeneration in ALS.

  2004cited by this paper
• RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia

  2004cited by this paper
• RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells.

  2004cited by this paper
• Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man.

  2004cited by this paper
• Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice

  2003cited by this paper
• AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

  2003cited by this paper
• Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model

  2003cited by this paper
• Killing the messenger: short RNAs that silence gene expression

  2003cited by this paper
• Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis

  2003cited by this paper
• Accumulation of SOD1 Mutants in Postnatal Motoneurons Does Not Cause Motoneuron Pathology or Motoneuron Disease

  2002cited by this paper
• A System for Stable Expression of Short Interfering RNAs in Mammalian Cells

  2002cited by this paper
• Neuron-Specific Expression of Mutant Superoxide Dismutase 1 in Transgenic Mice Does Not Lead to Motor Impairment

  2001cited by this paper
• Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1.

  1998cited by this paper
• Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus

  1998cited by this paper
• Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury

  1996cited by this paper
• Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons.

  1995cited by this paper

• Targets and Gene Therapy of ALS (Part 1)

  2025cites this paper
• AAV-NRIP gene therapy ameliorates motor neuron degeneration and muscle atrophy in ALS model mice

  2024cites this paper
• Variability in SOD1-associated amyotrophic lateral sclerosis: geographic patterns, clinical heterogeneity, molecular alterations, and therapeutic implications

  2024cites this paper
• In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification

  2024cites this paper
• Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives

  2023cites this paper
• Nanomedicine based strategies for oligonucleotide traversion across the blood-brain barrier.

  2023cites this paper
• Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents

  2022cites this paper
• Retrograde Axonal Transport Property of Adeno-Associated Virus and Its Possible Application in Future.

  2021cites this paper
• Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives.

  2021cites this paper
• Efficacy and long-term safety of CRISPR/Cas9 genome editing in the SOD1-linked mouse models of ALS

  2021cites this paper
• Treatment of a Mouse Model of ALS by In Vivo Base Editing.

  2020influential citation
• Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS)

  2020cites this paper
• RNA Dysregulation in Amyotrophic Lateral Sclerosis

  2019cites this paper
• RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis

  2018cites this paper
• SOD1 in Amyotrophic Lateral Sclerosis: “Ambivalent” Behavior Connected to the Disease

  2018cites this paper
• AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials

  2018cites this paper
• Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis

  2018cites this paper
• High content analysis in amyotrophic lateral sclerosis.

  2017cites this paper
• Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond

  2017cites this paper
• Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis

  2017cites this paper
• Title Future of rAAV gene therapy : Platform for RNAi , Gene Editing and Beyond Keywords : AAV vectors , Genome Editing , non-coding RNA , miRNA , RNAi

  2017cites this paper
• Silencing strategies for therapy of SOD1-mediated ALS.

  2017cites this paper
• Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis.

  2017cites this paper
• In vivo genome editing improves motor function and extends survival in a mouse model of ALS

  2017cites this paper
• Biomarkers in Neurodegenerative Diseases.

  2017cites this paper
• Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype

  2016cites this paper
• Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis

  2016cites this paper
• Defining SOD1 ALS natural history to guide therapeutic clinical trial design

  2016cites this paper
• Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model.

  2016cites this paper
• The Role of Skeletal Muscle in Amyotrophic Lateral Sclerosis

  2016cites this paper
• RNA-targeted Therapeutics for ALS

  2015cites this paper
• amyotrophic lateral sclerosis Respiratory impairment in a mouse model of

  2015cites this paper
• Use of biomarkers in ALS drug development and clinical trials.

  2015cites this paper
• Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

  2015cites this paper
• Astrocytes in neurodegenerative disease.

  2015cites this paper
• The role of wild-type SOD1 in SOD1 mouse models of ALS

  2014cites this paper
• Systemic gene delivery to the central nervous system using Adeno-associated virus

  2014cites this paper
• Application of Viral Vectors to Motor Neuron Disorders

  2014cites this paper
• Delayed Disease Onset and Extended Survival in the SOD1G93A Rat Model of Amyotrophic Lateral Sclerosis after Suppression of Mutant SOD1 in the Motor Cortex

  2014cites this paper
• Nanoparticles in the Brain: A Potential Therapeutic System Targeted to an Early Defect Observed in Many Neurodegenerative Diseases

  2013cites this paper
• Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS.

  2013cites this paper
• SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.

  2013cites this paper
• Human Neural Stem Cell Replacement Therapy for Amyotrophic Lateral Sclerosis by Spinal Transplantation

  2012cites this paper
• Advances in Induced Pluripotent Stem Cell Technologies

  2012cites this paper
• Glial Cells as Therapeutic Targets for ALS

  2012influential citation
• The advent of AAV9 expands applications for brain and spinal cord gene delivery

  2012cites this paper
• Prospect of Induced Pluripotent Stem Cell Genetic Repair to Cure Genetic Diseases

  2012cites this paper
• Prospect of Induced Pluripotent Stem Cell Genetic Repair to Cure Genetic Diseases

  2012cites this paper
• Musculotopic organization of the motor neurons supplying the mouse hindlimb muscles: a quantitative study using Fluoro-Gold retrograde tracing

  2012cites this paper
• Preclinical testing of potential therapeutics for Amyotrophic Lateral Sclerosis

  2012cites this paper
• RNAi Towards Functional Genomics Studies

  2012cites this paper
• Expression of microsomal prostaglandin E synthase-1 in the spinal cord in a transgenic mouse model of amyotrophic lateral sclerosis.

  2012cites this paper
• Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives.

  2011cites this paper
• Gene therapy of amyotrophic lateral sclerosis

  2011cites this paper
• Motor Neuron Diseases

  2011cites this paper
• Delivery Strategies for RNAi to the Nervous System

  2011cites this paper
• RNAi‐Mediated Therapeutics

  2011cites this paper
• New Treatments in Amyotrophic Lateral Sclerosis

  2011cites this paper
• Enhanced neuronal Met signalling levels in ALS mice delay disease onset

  2011cites this paper
• RNA interference and amyotrophic lateral sclerosis.

  2011cites this paper
• Amyotrophic Lateral Sclerosis

  2011cites this paper
• Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles.

  2011cites this paper
• Astrocytes from Familial and Sporadic ALS Patients are Toxic to Motor Neurons

  2011cites this paper
• New considerations in the design of clinical trials for amyotrophic lateral sclerosis.

  2011cites this paper
• Delivery of RNA interference triggers to sensory neurons in vivo using herpes simplex virus

  2010cites this paper
• Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6

  2010cites this paper
• Advances in Amyotrophic Lateral Sclerosis , 2009 to 2010

  2010cites this paper
• Collapsin Response Mediator Protein 4a (CRMP4a) Is Upregulated in Motoneurons of Mutant SOD1 Mice and Can Trigger Motoneuron Axonal Degeneration and Cell Death

  2010cites this paper
• RNAi therapeutics for CNS disorders.

  2010cites this paper
• Recent advances in the manipulation of murine gene expression and its utility for the study of human neurological disease.

  2010cites this paper
• Amyotrophic Lateral Sclerosis Pathogenesis: A Journey Through the Secretory Pathway

  2010cites this paper
• Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.

  2009cites this paper
• Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.

  2009cites this paper
• Managing amyotrophic lateral sclerosis: Slowing disease progression and improving patient quality of life

  2009cites this paper
• UNIVERSITY OF FLORIDA THESIS OR DISSERTATION FORMATTING TEMPLATE

  2009cites this paper
• Therapeutic Potential of Small Interfering RNA for Brain Diseases

  2009cites this paper
• Potential application of RNAi for understanding and therapy of neurodegenerative diseases.

  2009cites this paper
• microRNA a macro Revolution in Medical Biotechnologies

  2008cites this paper
• Gene-targeted therapies for the central nervous system.

  2008cites this paper
• Silencing mutant Huntingtin by RNA interference for the treatment of Huntington Disease

  2008cites this paper
• Mouse Models with Motor Neuron Defects as a Tool for Deciphering Amyotrophic Lateral Sclerosis

  2008cites this paper
• Drug therapy in amyotrophic lateral sclerosis.

  2008cites this paper
• RIBONUCLEIC ACID INTERFERENCE FOR NEUROLOGICAL DISORDERS: CANDIDATE DISEASES, POTENTIAL TARGETS, AND CURRENT APPROACHES

  2007cites this paper
• Prospects of treating neurological diseases by gene therapy.

  2007cites this paper
• Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis

  2007cites this paper
• Lost in translation: Treatment trials in the SOD1 mouse and in human ALS

  2007cites this paper
• Increase of disease duration of amyotrophic lateral sclerosis in a mouse model by transgenic small interfering RNA.

  2007cites this paper
• Oxidized/misfolded superoxide dismutase‐1: the cause of all amyotrophic lateral sclerosis?

  2007cites this paper
• Current clinical trials in amyotrophic lateral sclerosis

  2007cites this paper
• Gene therapy for disorders affecting children, progress and potential

  2007cites this paper
• Targeted Spinal Cord Therapeutics Delivery: Stabilized Platform and Microelectrode Recording Guidance Validation

  2007cites this paper
• Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease

  2007cites this paper
• Individualisation de l’entraînement physique chez la souris : influence du fonds génétique sur l’adaptation musculaire, applications aux maladies du motoneurone

  2007cites this paper
• Développement de vecteurs lentiviraux régulables pour le transfert de gène dans le système nerveux central

  2007cites this paper
• Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice

  2007cites this paper
• Respiratory impairment in a mouse model of amyotrophic lateral sclerosis.

  2007cites this paper
• Chapter 19 Therapies in amyotrophic lateral sclerosis: Options for the near and far future.

  2007cites this paper
• RNA interference: a tool for querying nervous system function and an emerging therapy.

  2007cites this paper
• Ribonucleic acid interference: the relevance of molecular targeting and therapeutics to neurosurgical practice.

  2007cites this paper
• Chapter 6 Animal models of motor neuron death.

  2007cites this paper